Universal Beteiligungs und Servicegesellschaft mbH Lowers Position in Vanda Pharmaceuticals Inc. $VNDA

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 88.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 20,000 shares of the biopharmaceutical company’s stock after selling 160,000 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Vanda Pharmaceuticals were worth $176,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of VNDA. Millennium Management LLC lifted its position in Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after purchasing an additional 1,470,898 shares in the last quarter. Marshall Wace LLP raised its holdings in Vanda Pharmaceuticals by 945.9% during the second quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock valued at $2,227,000 after acquiring an additional 426,620 shares during the period. Krensavage Asset Management LLC raised its holdings in Vanda Pharmaceuticals by 35.9% during the second quarter. Krensavage Asset Management LLC now owns 1,024,883 shares of the biopharmaceutical company’s stock valued at $4,837,000 after acquiring an additional 270,502 shares during the period. Qube Research & Technologies Ltd bought a new stake in Vanda Pharmaceuticals during the third quarter valued at about $894,000. Finally, Two Sigma Investments LP raised its holdings in Vanda Pharmaceuticals by 25.7% during the third quarter. Two Sigma Investments LP now owns 662,305 shares of the biopharmaceutical company’s stock valued at $3,305,000 after acquiring an additional 135,439 shares during the period. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vanda Pharmaceuticals

In related news, CFO Kevin Patrick Moran sold 42,442 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $350,995.34. Following the completion of the sale, the chief financial officer owned 411,380 shares in the company, valued at approximately $3,402,112.60. The trade was a 9.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mihael Hristos Polymeropoulos sold 156,235 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $8.17, for a total value of $1,276,439.95. Following the completion of the sale, the chief executive officer owned 2,704,496 shares of the company’s stock, valued at $22,095,732.32. The trade was a 5.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 314,342 shares of company stock valued at $2,583,985 in the last ninety days. Corporate insiders own 10.00% of the company’s stock.

Wall Street Analyst Weigh In

VNDA has been the topic of a number of recent analyst reports. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. HC Wainwright raised their price target on Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Monday, April 20th. Truist Financial initiated coverage on Vanda Pharmaceuticals in a report on Thursday, March 5th. They set a “buy” rating and a $18.00 price target on the stock. Finally, Zacks Research cut Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.90.

Vanda Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ:VNDA opened at $7.44 on Thursday. Vanda Pharmaceuticals Inc. has a 1 year low of $3.81 and a 1 year high of $9.94. The business has a 50 day simple moving average of $7.60 and a two-hundred day simple moving average of $6.79. The firm has a market capitalization of $447.40 million, a PE ratio of -1.99 and a beta of 0.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.39 and a quick ratio of 2.38.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. The business had revenue of $51.72 million for the quarter, compared to analysts’ expectations of $54.98 million. On average, equities analysts predict that Vanda Pharmaceuticals Inc. will post -2.18 EPS for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.